Company description

Cellectis S.A. (CLLS) is a leading biotechnology company focused on developing innovative therapies for cancer patients. Founded in 1999, the Paris-based company utilizes cutting-edge technologies, such as gene editing and CAR-T cell engineering, to create personalized treatments for a variety of cancers. Their flagship product, UCART19, is a revolutionary CAR-T cell therapy being developed for the treatment of acute lymphoblastic leukemia (ALL) and other B-cell malignancies. With a strong pipeline of potential therapies, Cellectis is dedicated to advancing the field of immuno-oncology and transforming the way cancer is treated. In addition to their groundbreaking research and development efforts, the company also collaborates with other leading pharmaceutical companies to expand their reach and impact in the industry. With a mission to improve the lives of cancer patients, Cellectis is a company that continues to push the boundaries of science and provide hope for a future without cancer.